Literature DB >> 15525837

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.

Boris Fehse, Francis A Ayuk, Nicolaus Kröger, Lubin Fang, Klaus Kühlcke, Marion Heinzelmann, Tatjana Zabelina, Axel A Fauser, Axel R Zander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15525837     DOI： 10.1182/blood-2004-07-2813

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

2.  Haploidentical HSCT: a 15-year experience at San Raffaele.

Authors:  C Bonini; J Peccatori; M T L Stanghellini; L Vago; A Bondanza; N Cieri; R Greco; M Bernardi; C Corti; G Oliveira; E Zappone; C Traversari; C Bordignon; F Ciceri
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 3.  Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

Authors:  Kenzaburo Tani
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

4.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

5.  An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.

Authors:  Isabel Vogler; Sebastian Newrzela; Sylvia Hartmann; Nadine Schneider; Dorothee von Laer; Ulrike Koehl; Manuel Grez
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

6.  Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.

Authors:  M Pincha; G Salguero; D Wedekind; B S Sundarasetty; A Lin; N Kasahara; M H Brugman; A C Jirmo; U Modlich; R Gutzmer; G Büsche; A Ganser; R Stripecke
Journal:  Gene Ther       Date:  2011-03-17       Impact factor: 5.250

Review 7.  Improving the safety of cell therapy with the TK-suicide gene.

Authors:  Raffaella Greco; Giacomo Oliveira; Maria Teresa Lupo Stanghellini; Luca Vago; Attilio Bondanza; Jacopo Peccatori; Nicoletta Cieri; Sarah Marktel; Sara Mastaglio; Claudio Bordignon; Chiara Bonini; Fabio Ciceri
Journal:  Front Pharmacol       Date:  2015-05-05       Impact factor: 5.810

8.  Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene.

Authors:  Hong Zhan; Kimberly Gilmour; Lucas Chan; Farzin Farzaneh; Anne Marie McNicol; Jin-Hua Xu; Stuart Adams; Boris Fehse; Paul Veys; Adrian Thrasher; Hubert Gaspar; Waseem Qasim
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

9.  Retroviral gene therapy in Germany with a view on previous experience and future perspectives.

Authors:  Michael A Morgan; Melanie Galla; Manuel Grez; Boris Fehse; Axel Schambach
Journal:  Gene Ther       Date:  2021-03-22       Impact factor: 5.250
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.